当前位置:首页 - 行情中心 - 和元生物(688238) - 财务分析 - 现金流量表

和元生物

(688238)

  

流通市值:50.76亿  总市值:50.88亿
流通股本:6.47亿   总股本:6.49亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金136,779,461.9448,630,562.32257,555,229.9184,194,824.98
  收到其他与经营活动有关的现金7,829,467.275,750,101.7528,663,348.188,754,656.15
  经营活动现金流入小计144,608,929.2154,380,664.07286,218,578.08192,949,481.13
  购买商品、接受劳务支付的现金75,921,738.6340,109,253.66143,608,557.22111,382,774.08
  支付给职工以及为职工支付的现金99,760,850.5849,882,134.21188,568,976.14145,674,984.89
  支付的各项税费6,953,183.213,466,683.7211,675,367.158,167,745.62
  支付其他与经营活动有关的现金44,889,477.5126,994,825.1944,960,622.5338,304,791.93
  经营活动现金流出小计227,525,249.93120,452,896.78388,813,523.04303,530,296.52
  经营活动产生的现金流量净额-82,916,320.72-66,072,232.71-102,594,944.96-110,580,815.39
二、投资活动产生的现金流量:
  收回投资收到的现金80,000,00030,000,000313,685,358.8223,685,358.8
  取得投资收益收到的现金437,939.0917,532.181,439,028.551,083,401.26
  处置固定资产、无形资产和其他长期资产收回的现金净额--1,321,9101,201,000
  收到的其他与投资活动有关的现金--34,604,082.4834,604,082.48
  投资活动现金流入小计80,437,939.0930,017,532.18351,050,379.83260,573,842.54
  购建固定资产、无形资产和其他长期资产支付的现金54,436,480.8131,655,989.08126,243,412.59104,909,985.5
  投资支付的现金99,650,00081,650,000314,000,000265,000,000
  取得子公司及其他营业单位支付的现金--116,922.06116,922.06
  支付其他与投资活动有关的现金--21,221,013.7421,221,013.74
  投资活动现金流出小计154,086,480.81113,305,989.08461,581,348.39391,247,921.3
  投资活动产生的现金流量净额-73,648,541.72-83,288,456.9-110,530,968.56-130,674,078.76
三、筹资活动产生的现金流量:
  吸收投资收到的现金1,650,0001,650,000--
  其中:子公司吸收少数股东投资收到的现金1,650,000---
  取得借款收到的现金185,000,000115,000,000280,000,000234,903,753.27
  筹资活动现金流入小计186,650,000116,650,000280,000,000234,903,753.27
  偿还债务支付的现金151,217,000118,483,500101,044,371.2686,200,500
  分配股利、利润或偿付利息支付的现金4,840,165.32,434,797.598,348,247.285,907,487.57
  支付其他与筹资活动有关的现金3,208,679.7674,194.17101,803,652.48101,739,001.89
  筹资活动现金流出小计159,265,845.06120,992,491.76211,196,271.02193,846,989.46
  筹资活动产生的现金流量净额27,384,154.94-4,342,491.7668,803,728.9841,056,763.81
四、汇率变动对现金及现金等价物的影响-109,542.46-50,528.32-20,263.68-66,210.72
五、现金及现金等价物净增加额-129,290,249.96-153,753,709.69-144,342,448.22-200,264,341.06
  加:期初现金及现金等价物余额290,551,803.61290,551,803.61434,894,251.83434,894,251.83
  期末现金及现金等价物余额161,261,553.65136,798,093.92290,551,803.61234,629,910.77
补充资料:
  净利润-101,559,075.74--234,810,012.67-
  资产减值准备1,737,710.45-22,903,467.32-
  固定资产和投资性房地产折旧47,263,663.72-93,224,306.35-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧47,263,663.72-93,224,306.35-
  无形资产摊销1,161,717.31-2,086,518.97-
  长期待摊费用摊销1,360,266.78-2,720,533.56-
  处置固定资产、无形资产和其他长期资产的损失--1,072,763.43-
  公允价值变动损失-248,450.39--86,487.4-
  财务费用5,161,538.85-8,634,944.92-
  投资损失806,043.2--6,089,808.86-
  递延所得税332,119.93-1,598,591.27-
  其中:递延所得税资产减少938,775.48--1,431,170.67-
    递延所得税负债增加-606,655.55-3,029,761.94-
  存货的减少-12,926,920.45-1,341,469.12-
  经营性应收项目的减少-37,932,665.26--33,990,586.92-
  经营性应付项目的增加5,281,086.41-33,167,175.79-
  其他1,514,995.06-1,339,323.69-
  现金的期末余额161,261,553.65-290,551,803.61-
  减:现金的期初余额290,551,803.61-434,894,251.83-
  现金及现金等价物的净增加额-129,290,249.96--144,342,448.22-
公告日期2026-08-252026-04-282026-04-212025-10-28
审计意见(境内)标准无保留意见
TOP↑